Related Experiment Videos
Antisense MBD2 gene therapy inhibits tumorigenesis
Andrew Slack1, Veronica Bovenzi, Pascal Bigey
1Department of Pharmacology and Therapeutics, McGill University, 3655 Drummond Street, Montreal, PQ H3G 1Y6, Canada.
The Journal of Gene Medicine
|July 19, 2002
Summary
Dysregulation of Methyl-CpG Binding Domain protein 2 (MBD2) is implicated in cancer. Inhibiting MBD2 shows promise as an anticancer strategy by reducing tumor growth.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Aberrant DNA methylation patterns are characteristic of cancer.
- Methyl-CpG Binding Domain protein 2 (MBD2), a DNA-binding protein, is implicated in tumorigenesis.
- MBD2 possesses DNA demethylase activity and represses methylated genes.
Purpose of the Study:
- To investigate the role of MBD2 in tumorigenesis.
- To evaluate MBD2 as a potential anticancer target.
Main Methods:
- Utilized antisense expression and delivery systems, including transfection, electrotransfer, and adenoviral vectors.
- Assessed MBD2's essentiality in tumorigenesis both ex vivo and in vivo.
Main Results:
- Antisense inhibition of MBD2 suppressed anchorage-independent growth of cancer cells.
- Adenoviral or electrotransfer delivery of MBD2 antisense reduced xenograft tumor growth.
Conclusions:
- MBD2's functions are critical in tumorigenesis.
- MBD2 represents a potential therapeutic target for anticancer strategies.